-+ 0.00%
-+ 0.00%
-+ 0.00%

The General Office of the Xi'an Municipal People's Government issued the “Implementation Plan to Promote Capacity Enhancement in the Biomedical Industry”, which proposes to promote contract research and development services. Encourage enterprises that are in a position to do so to split surplus production capacity to provide CRO/CDMO services to other enterprises. Support existing CRO companies to continue to expand laboratory R&D space, introduce pilot service platforms, focus on leading existing cooperative companies to lay out innovative drug projects, and develop innovative drug business cooperation with manufacturers to achieve transformation from CRO to CXO. Encourage biomedical industrial parks to connect and introduce leading domestic contract R&D, R&D, production, and manufacturing enterprises, and attract them to set up regional headquarters or branches through policy support and carrier co-construction to establish a full-chain service network covering “drug discovery - pre-clinical research - clinical trials - production transformation”.

Zhitongcaijing·12/17/2025 06:49:04
Listen to the news
The General Office of the Xi'an Municipal People's Government issued the “Implementation Plan to Promote Capacity Enhancement in the Biomedical Industry”, which proposes to promote contract research and development services. Encourage enterprises that are in a position to do so to split surplus production capacity to provide CRO/CDMO services to other enterprises. Support existing CRO companies to continue to expand laboratory R&D space, introduce pilot service platforms, focus on leading existing cooperative companies to lay out innovative drug projects, and develop innovative drug business cooperation with manufacturers to achieve transformation from CRO to CXO. Encourage biomedical industrial parks to connect and introduce leading domestic contract R&D, R&D, production, and manufacturing enterprises, and attract them to set up regional headquarters or branches through policy support and carrier co-construction to establish a full-chain service network covering “drug discovery - pre-clinical research - clinical trials - production transformation”.